Rafael Holdings Q2 net loss $4.6M vs prior year net income; merger with Cyclo pending

Rafael Holdings, Inc.

2025-Q2 EPS reported -$0.57 revenue$205,000

Net loss of $4.6M ($0.19/sh) for Q2 ended Jan 31, 2025 vs net income of $6.0M ($0.25/sh) a year ago.
Cash and equivalents at $48.3M as of January 31, 2025.
Merger with Cyclo Therapeutics (CYTH) expected to close in Q3 fiscal 2025 pending shareholder approvals.
Topline data from interim analysis (48 weeks) of Phase 3 Trappsol Cyclo for NPC1 expected mid-2025.
R&D expenses rose to $0.9M from $0.6M due to consolidation of Cornerstone and Day Three.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.